explore the role of blood-based tumor mutation burden in predicting outcomes to immune checkpoint inhibitors in patients with advanced breast or prostate cancers. They find immune checkpoint inhibitors were not offered based on blood-based tumor mutation burden, and this did not predict response....
Tumor mutational burden (TMB) in circulating tumor DNA (ctDNA) has shown promise in predicting benefit from PD-L1/PD-1 inhibitors in retrospective studies. Aiming to assess blood TMB (bTMB) prospectively, we conducted B-F1RST (NCT02848651), an open-label, phase 2 trial that evaluated bTMB ...
Although programmed death-ligand 1–programmed death 1 (PD-L1–PD-1) inhibitors are broadly efficacious, improved outcomes have been observed in patients with high PD-L1 expression or high tumor mutational burden (TMB). PD-L1 testing is required for checkpoint inhibitor monotherapy in front-line ...
Abstract 3376: Non-small cell lung cancer (NSCLC) with higher blood tumor mutational burden (bTMB)/tissueTMB (tTMB) ratio is associated with inferior survival outcome doi:10.1158/1538-7445.AM2023-3376Background: High TMB is known to correlate with better response to immune checkpoint inhibitor (...
tumor mutational burden (TMB)Background and Objective: For patients with metastatic non-small cell lung cancer (NSCLC) without an oncogenic driver, systemic therapy with immune checkpoint inhibitors (ICIs) alone or in combination with chemotherapy have significantly improved the outcomes. However, the ...
Abbreviations bITH: Blood-based intratumor heterogeneity; bTMB: Blood-based tumor mutational burden; cfDNA: Circulating cell-free DNA; CRP: C-reactive protein (CRP); ctDNA: Circulating tumor DNA; DCB: Durable clinical benefits; DCBc: Durable clinical benefits from ICIs-based combination therapy; ...
Tumor mutational burden (TMB), defined as the total number of somatic mutations per megabase of the tumor genome, is another tissue-based biomarker that has been explored to predict clinical outcomes to ICI [16]. It is postulated that more neoantigens induce greater immune activation, with some...
With a simple blood draw, researchers can screen for mutations in 500 different genes. They used thisliquid biopsypanel to measure the tumor mutational burden (TMB) - essentially the number of mutations detectable in the blood—of 66 patients, 52 of whom were evaluable for this trial. TMB is...
26have shown that blood-based tumor mutational burden (bTMB) is an attractive alternative to tissue-based TMB due to three advantages: (1) noninvasiveness, (2) more comprehensive mutation coverage (by cfDNA) than a single-site tumor biopsy, and (3) the VAFs of mutations in cfDNA reflect ...
Tumor mutational burden (TMB) is being explored as a predictive biomarker for cancer immunotherapy outcomes in non-small cell lung cancer. BFAST (NCT03178552)—an open-label, global, multicohort trial—evaluated the safety and efficacy of first-line targeted therapies or immunotherapy in patients wi...